You are viewing the site in preview mode

Skip to main content

Table 3 Correlation analysis for ∆ FABP4

From: Treatment with anagliptin, a DPP-4 inhibitor, decreases FABP4 concentration in patients with type 2 diabetes mellitus at a high risk for cardiovascular disease who are receiving statin therapy

  Total (n = 307) Anagliptin (n = 148) Sitagliptin (n = 159)
r P r P r P
Age at baseline − 0.04 0.47 − 0.03 0.73 − 0.06 0.49
FABP4 at baseline − 0.46 < 0.01 − 0.59 < 0.01 − 0.30 < 0.01
∆ body mass index 0.05 0.41 − 0.09 0.26 0.20 0.01
∆ waist circumference 0.15 0.01 0.00 0.96 0.33 < 0.01
∆ AST − 0.10 0.07 − 0.02 0.83 − 0.21 0.01
∆ ALT − 0.06 0.26 − 0.05 0.56 − 0.11 0.19
∆ γGTP − 0.14 < 0.01 0.01 0.89 − 0.23 < 0.01
∆ blood urea nitrogen 0.21 < 0.01 0.20 0.01 0.21 0.01
∆ creatinine 0.28 < 0.01 0.33 < 0.01 0.24 < 0.01
∆ eGFR − 0.18 < 0.01 − 0.20 0.01 − 0.15 0.06
∆ total cholesterol 0.04 0.47 0.02 0.80 0.03 0.66
∆ LDL cholesterol 0.05 0.42 0.00 0.97 0.08 0.35
∆ HDL cholesterol − 0.05 0.41 − 0.15 0.07 0.04 0.59
∆ triglycerides 0.04 0.43 0.14 0.08 − 0.08 0.29
∆ fasting glucose 0.01 0.88 0.01 0.87 0.00 0.96
∆ insulin 0.05 0.40 0.00 0.97 0.15 0.06
∆ HbA1c 0.02 0.74 − 0.01 0.87 0.05 0.54
  1. ∆, change calculated as parameter in 52 weeks minus that in baseline
  2. AST aspartate transaminase, ALT alanine transaminase, eGFR estimated glomerular filtration rate, γGTP γ-glutamyl transpeptidase
Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840